PanGIA Biotech Presents AI-Powered Urine Test for Early Prostate Cancer Detection at ASCO 2025

Chicago—(Business Wire)—PanGIA Biotech, a pioneer in non-invasive cancer diagnostics, recently unveiled promising findings at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO). The company's AI-enabled, urine-based testing platform, PanGIA®, has successfully undergone a multi-center validation study, marking the first clinical validation of its innovative approach to detecting early-stage prostate cancer. The study, titled "Development and Validation of an AI-Enabled Prediction of Prostate Cancer (PCa) Using Urine-Based Liquid Biopsy" (Abstract #3080), demonstrates the effectiveness of PanGIA's method, which combines proprietary chemical analysis techniques with advanced machine learning algorithms. This unique combination allows for the detection of cancer-specific biosignatures from a simple, non-invasive urine sample, thus eliminating the need for costly and invasive biopsies or blood tests that can often overlook early-stage cases. "We are thrilled to see our hypothesis confirmed through clinical data," stated Holly Magliochetti, CEO of PanGIA Biotech. "Our platform offers a powerful, data-driven solution that enables early detection, providing clinicians with a tool to intervene when treatment is most likely to be successful and effective." One of the key advantages of the PanGIA® platform is its ability to analyze urinary biosignatures using artificial intelligence, bypassing the need for complex and expensive sequencing processes. This feature not only reduces the overall cost but also enhances the test's scalability, making it a viable option for a wide range of healthcare settings, from rural clinics to urban hospitals. PanGIA Biotech's technology has already garnered recognition, including a publication in The Analyst, a journal of the Royal Society of Chemistry. The study, “A Colorimetric Chemical Tongue Detects and Distinguishes Between Multiple Analytes,” highlighted the platform's potential for broad global adoption due to its simplicity and reliability. About PanGIA Biotech PanGIA Biotech is dedicated to advancing healthcare through AI-integrated, urine-based liquid biopsy solutions. The PanGIA® platform is designed to support early detection, monitoring, and disease management, including identifying cancer as early as Stage 1. By leveraging machine learning to interpret complex biomolecular patterns, the platform provides accurate diagnostic insights in a user-friendly manner. Supported by robust patents and peer-reviewed research, PanGIA is committed to revolutionizing cancer diagnostics and improving patient outcomes. For more information, visit www.PanGIABiotech.com. References Lim FB, et al. “A Colorimetric Chemical Tongue Detects and Distinguishes Between Multiple Analytes.” The Analyst. 2022;147(23):5283–5292. doi:10.1039/D2AN01615J For additional updates and news from PanGIA Biotech, stay tuned to their official communications.